Abstract
Ribotoxins constitute a family of toxic extracellular fungal RNases that exert a highly specific activity on a conserved region of the larger molecule of rRNA, known as the sarcin – ricin loop. This cleavage of a single phosphodiester bond inactivates the ribosome and leads to protein synthesis inhibition and cell death. In addition to this ribonucleolytic activity, ribotoxins can cross lipid membranes in the absence of any known protein receptor. This ability is due to their capacity to interact with acid phospholipid-containing membranes. Both activities together explain their cytotoxic character, being rather specific when assayed against some transformed cell lines. The determination of high-resolution structures of some ribotoxins, the characterization of a large number of mutants, and the use of lipid model vesicles and transformed cell lines have been the tools used for the study of their mechanism of action at the molecular level. The present knowledge suggests that wild-type ribotoxins or some modified variants might be used in human therapies. Production of hypoallergenic mutants and immunotoxins designed against specific tumors stand out as feasible alternatives to treat some human pathology in the mid-term future.
Keywords: Asp f 1, fungal allergy, immunotoxin, restrictocin, Rnase, α-sarcin
Current Pharmaceutical Biotechnology
Title: The Therapeutic Potential of Fungal Ribotoxins
Volume: 9 Issue: 3
Author(s): Nelson Carreras-Sangra, Elisa Alvarez-Garcia, Elias Herrero-Galan, Jaime Tome, Javier Lacadena, Jorge Alegre-Cebollada, Mercedes Onaderra, Jose G. Gavilanes and Alvaro Martinez-del-Pozo
Affiliation:
Keywords: Asp f 1, fungal allergy, immunotoxin, restrictocin, Rnase, α-sarcin
Abstract: Ribotoxins constitute a family of toxic extracellular fungal RNases that exert a highly specific activity on a conserved region of the larger molecule of rRNA, known as the sarcin – ricin loop. This cleavage of a single phosphodiester bond inactivates the ribosome and leads to protein synthesis inhibition and cell death. In addition to this ribonucleolytic activity, ribotoxins can cross lipid membranes in the absence of any known protein receptor. This ability is due to their capacity to interact with acid phospholipid-containing membranes. Both activities together explain their cytotoxic character, being rather specific when assayed against some transformed cell lines. The determination of high-resolution structures of some ribotoxins, the characterization of a large number of mutants, and the use of lipid model vesicles and transformed cell lines have been the tools used for the study of their mechanism of action at the molecular level. The present knowledge suggests that wild-type ribotoxins or some modified variants might be used in human therapies. Production of hypoallergenic mutants and immunotoxins designed against specific tumors stand out as feasible alternatives to treat some human pathology in the mid-term future.
Export Options
About this article
Cite this article as:
Carreras-Sangra Nelson, Alvarez-Garcia Elisa, Herrero-Galan Elias, Tome Jaime, Lacadena Javier, Alegre-Cebollada Jorge, Onaderra Mercedes, Gavilanes G. Jose and Martinez-del-Pozo Alvaro, The Therapeutic Potential of Fungal Ribotoxins, Current Pharmaceutical Biotechnology 2008; 9 (3) . https://dx.doi.org/10.2174/138920108784567335
DOI https://dx.doi.org/10.2174/138920108784567335 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Mechanisms of Anticancer Agents by Genistein and Synthetic Derivatives of Isoflavone
Mini-Reviews in Medicinal Chemistry Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Skp2 Inhibitors: Novel Anticancer Strategies
Current Medicinal Chemistry Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Inhibition of HIV-1 Replication by RNA-Based Strategies
Current HIV Research Treatment of Pancreatic Cancer with Pharmacological Ascorbate
Current Pharmaceutical Biotechnology Fighting Tumor Cell Survival: Advances in the Design and Evaluation of Pim Inhibitors
Current Medicinal Chemistry Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry β -TrCP Dependency of HIV-1 Vpu-Induced Downregulation of CD4 and BST-2/Tetherin
Current HIV Research Biomacromolecule-Functionalized Nanoparticle-Based Conjugates for Potentiation of Anticancer Therapy
Current Cancer Drug Targets New Biomarkers for Colon Cancer Diagnosis: A Review of Recent Patents
Recent Patents on Biomarkers Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
Current Enzyme Inhibition Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Aspartic Protease Inhibitors: Effective Drugs against the Human Fungal Pathogen Candida albicans
Mini-Reviews in Medicinal Chemistry Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Withdrawn: Alkaloidal Content, Medicinal, Properties of Peganum harmala L. (P. harmala)
Current Traditional Medicine Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets